Chenghao Pan Selected Research

ErbB Receptors (EGF Receptor)

4/2024

Design, synthesis, and antitumor activity evaluation of potent fourth-generation EGFR inhibitors for treatment of Osimertinib resistant non-small cell lung cancer (NSCLC).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Chenghao Pan Research Topics

Disease

4	Neoplasms (Cancer) 11/2022 - 03/2021
2	Hepatocellular Carcinoma (Hepatoma) 01/2022 - 12/2021
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2024
1	Colorectal Neoplasms (Colorectal Cancer) 09/2022
1	Hypoxia (Hypoxemia) 01/2022

Drug/Important Bio-Agent (IBA)

2	Peptides (Polypeptides)IBA 11/2022 - 03/2021
2	Proteins (Proteins, Gene)FDA Link 11/2022 - 01/2022
2	LigandsIBA 01/2022 - 03/2021
1	ErbB Receptors (EGF Receptor)IBA 04/2024
1	osimertinibIBA 04/2024
1	UbiquitinIBA 11/2022
1	Fluorescent Dyes (Fluorescent Probes)IBA 09/2022
1	Biotin (Vitamin H)FDA Link 09/2022
1	Von Hippel-Lindau Tumor Suppressor ProteinIBA 01/2022
1	Type 4 Fibroblast Growth Factor ReceptorIBA 01/2022
1	Immune Checkpoint InhibitorsIBA 01/2022
1	Growth Factor ReceptorsIBA 12/2021
1	Fibroblast Growth Factors (Fibroblast Growth Factor)IBA 12/2021
1	Blocking AntibodiesIBA 03/2021
1	B7-H1 AntigenIBA 03/2021
1	Monoclonal AntibodiesIBA 03/2021

Therapy/Procedure

2	Immunotherapy 01/2022 - 03/2021